vs
Side-by-side financial comparison of CF BANKSHARES INC. (CFBK) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
CF BANKSHARES INC. is the larger business by last-quarter revenue ($15.7M vs $9.1M, roughly 1.7× Protalix BioTherapeutics, Inc.). CF BANKSHARES INC. runs the higher net margin — 40.0% vs -60.3%, a 100.4% gap on every dollar of revenue. On growth, CF BANKSHARES INC. posted the faster year-over-year revenue change (12.6% vs -49.9%). CF BANKSHARES INC. produced more free cash flow last quarter ($18.2M vs $1.6M). Over the past eight quarters, CF BANKSHARES INC.'s revenue compounded faster (13.7% CAGR vs -6.7%).
CF Bankshares Inc. is a U.S.-based regional bank holding company operating through its community bank subsidiary. It offers a full suite of personal and commercial banking solutions including deposit products, various loan options, wealth management services and digital banking tools, primarily serving individual consumers and small-to-medium business clients across the U.S. Midwest region.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
CFBK vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.7M | $9.1M |
| Net Profit | $5.7M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | 43.4% | -51.1% |
| Net Margin | 40.0% | -60.3% |
| Revenue YoY | 12.6% | -49.9% |
| Net Profit YoY | 29.9% | -184.8% |
| EPS (diluted) | $0.88 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.7M | $9.1M | ||
| Q3 25 | $15.5M | $17.9M | ||
| Q2 25 | $15.6M | $15.7M | ||
| Q1 25 | $14.1M | $10.1M | ||
| Q4 24 | $14.0M | $18.2M | ||
| Q3 24 | $13.1M | $18.0M | ||
| Q2 24 | $12.6M | $13.5M | ||
| Q1 24 | $12.2M | — |
| Q4 25 | $5.7M | $-5.5M | ||
| Q3 25 | $2.3M | $2.4M | ||
| Q2 25 | $5.0M | $164.0K | ||
| Q1 25 | $4.4M | $-3.6M | ||
| Q4 24 | $4.4M | $6.5M | ||
| Q3 24 | $4.2M | $3.2M | ||
| Q2 24 | $1.7M | $-2.2M | ||
| Q1 24 | $3.1M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 43.4% | -51.1% | ||
| Q3 25 | 17.5% | 11.9% | ||
| Q2 25 | 41.1% | 7.5% | ||
| Q1 25 | 39.5% | -41.0% | ||
| Q4 24 | 36.9% | 39.6% | ||
| Q3 24 | 40.4% | 22.2% | ||
| Q2 24 | 15.4% | -18.0% | ||
| Q1 24 | 30.9% | — |
| Q4 25 | 40.0% | -60.3% | ||
| Q3 25 | 15.1% | 13.2% | ||
| Q2 25 | 32.3% | 1.0% | ||
| Q1 25 | 31.4% | -35.8% | ||
| Q4 24 | 35.2% | 35.6% | ||
| Q3 24 | 32.2% | 18.0% | ||
| Q2 24 | 13.5% | -16.4% | ||
| Q1 24 | 25.2% | — |
| Q4 25 | $0.88 | $-0.06 | ||
| Q3 25 | $0.36 | $0.03 | ||
| Q2 25 | $0.77 | $0.00 | ||
| Q1 25 | $0.68 | $-0.05 | ||
| Q4 24 | $0.68 | $0.10 | ||
| Q3 24 | $0.65 | $0.03 | ||
| Q2 24 | $0.26 | $-0.03 | ||
| Q1 24 | $0.47 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $184.4M | $48.2M |
| Total Assets | $2.1B | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $259.0M | $14.7M | ||
| Q3 25 | $272.4M | $13.6M | ||
| Q2 25 | $275.7M | $17.9M | ||
| Q1 25 | $241.0M | $19.5M | ||
| Q4 24 | $235.3M | $19.8M | ||
| Q3 24 | $233.5M | $27.4M | ||
| Q2 24 | $241.8M | $23.4M | ||
| Q1 24 | $236.9M | — |
| Q4 25 | $184.4M | $48.2M | ||
| Q3 25 | $179.3M | $52.9M | ||
| Q2 25 | $177.0M | $49.9M | ||
| Q1 25 | $172.7M | $45.2M | ||
| Q4 24 | $168.4M | $43.2M | ||
| Q3 24 | $164.0M | $32.4M | ||
| Q2 24 | $159.6M | $28.6M | ||
| Q1 24 | $158.0M | — |
| Q4 25 | $2.1B | $82.3M | ||
| Q3 25 | $2.1B | $82.3M | ||
| Q2 25 | $2.1B | $78.5M | ||
| Q1 25 | $2.1B | $73.9M | ||
| Q4 24 | $2.1B | $73.4M | ||
| Q3 24 | $2.1B | $61.6M | ||
| Q2 24 | $2.0B | $91.5M | ||
| Q1 24 | $2.0B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.7M | $2.0M |
| Free Cash FlowOCF − Capex | $18.2M | $1.6M |
| FCF MarginFCF / Revenue | 115.6% | 17.8% |
| Capex IntensityCapex / Revenue | 3.1% | 4.4% |
| Cash ConversionOCF / Net Profit | 3.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $33.4M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.7M | $2.0M | ||
| Q3 25 | $5.5M | $-3.7M | ||
| Q2 25 | $8.0M | $-5.2M | ||
| Q1 25 | $2.2M | $-5.1M | ||
| Q4 24 | $14.2M | $4.0M | ||
| Q3 24 | $-1.3M | $4.1M | ||
| Q2 24 | $4.0M | $-3.6M | ||
| Q1 24 | $-1.2M | — |
| Q4 25 | $18.2M | $1.6M | ||
| Q3 25 | $5.2M | $-4.2M | ||
| Q2 25 | $7.8M | $-5.7M | ||
| Q1 25 | $2.2M | $-5.4M | ||
| Q4 24 | $13.9M | $3.6M | ||
| Q3 24 | $-1.3M | $4.0M | ||
| Q2 24 | $4.0M | $-3.8M | ||
| Q1 24 | $-1.2M | — |
| Q4 25 | 115.6% | 17.8% | ||
| Q3 25 | 33.6% | -23.7% | ||
| Q2 25 | 50.3% | -36.2% | ||
| Q1 25 | 15.2% | -53.0% | ||
| Q4 24 | 99.6% | 19.6% | ||
| Q3 24 | -9.9% | 22.4% | ||
| Q2 24 | 31.6% | -28.1% | ||
| Q1 24 | -9.5% | — |
| Q4 25 | 3.1% | 4.4% | ||
| Q3 25 | 1.7% | 2.8% | ||
| Q2 25 | 0.7% | 2.8% | ||
| Q1 25 | 0.4% | 3.0% | ||
| Q4 24 | 1.9% | 2.3% | ||
| Q3 24 | 0.2% | 0.5% | ||
| Q2 24 | 0.1% | 1.3% | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 3.26× | — | ||
| Q3 25 | 2.34× | -1.58× | ||
| Q2 25 | 1.58× | -31.91× | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 3.21× | 0.61× | ||
| Q3 24 | -0.30× | 1.27× | ||
| Q2 24 | 2.35× | — | ||
| Q1 24 | -0.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CFBK
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
